Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals industries. The company operates in two segments, Pharmaceuticals and Crop Protection. It provides anti-convulsant, anti-inflammatory, analges...
Hikal reported revenue of 18.44 billion INR for fiscal year 2025, up 4.2% from fiscal year 2024, and net income of 908.00 million INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 4.91 billion INR, up 11.8% from a year before. Its largest business segment, Pharmaceuticals, brought in 63% of segment revenue in fiscal year 2025; India was the largest region with 38%. Its market capitalization was 26.34 billion INR as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2025; market data as of October 9, 2026.
No profile data available.